BioCryst Pharmaceuticals Inc
BCRX7.290USD
+0.160+2.24%
Close 12/18, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
More Details of BioCryst Pharmaceuticals Inc Company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BioCryst Pharmaceuticals Inc Info
Ticker SymbolBCRX
Company nameBioCryst Pharmaceuticals Inc
IPO dateMar 04, 1994
CEOGayer (Charles K)
Number of employees580
Security typeOrdinary Share
Fiscal year-endMar 04
Address4505 Emperor Blvd Ste 200
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27703-8457
Phone19198591302
Websitehttps://www.biocryst.com/
Ticker SymbolBCRX
IPO dateMar 04, 1994
CEOGayer (Charles K)
Company Executives of BioCryst Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
144.35K
-32.87%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
91.22K
+0.87%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
41.79K
+1.91%
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
144.35K
-32.87%
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
91.22K
+0.87%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States (Country)
140.34M
85.91%
Outside of U.S.
16.50M
10.10%
Other
6.52M
3.99%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.03%
RA Capital Management, LP
7.27%
Deerfield Management Company, L.P.
5.78%
State Street Investment Management (US)
4.66%
Other
63.93%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.03%
RA Capital Management, LP
7.27%
Deerfield Management Company, L.P.
5.78%
State Street Investment Management (US)
4.66%
Other
63.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.09%
Investment Advisor/Hedge Fund
27.37%
Hedge Fund
21.91%
Venture Capital
7.27%
Research Firm
6.22%
Individual Investor
1.12%
Pension Fund
0.77%
Private Equity
0.43%
Bank and Trust
0.38%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
564
213.88M
103.62%
+15.67M
2025Q3
578
198.21M
105.86%
-3.39M
2025Q2
567
200.28M
97.51%
+20.52M
2025Q1
541
179.39M
95.89%
-21.22M
2024Q4
539
169.89M
99.17%
-5.66M
2024Q3
532
176.74M
101.53%
-3.05M
2024Q2
510
179.40M
103.13%
-5.65M
2024Q1
522
185.07M
103.37%
-28.22M
2023Q4
527
182.31M
101.91%
+1.15M
2023Q3
518
181.69M
109.53%
+2.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
20.50M
9.77%
-1.12M
-5.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
17.04M
8.12%
-849.42K
-4.75%
Jun 30, 2025
Deerfield Management Company, L.P.
12.17M
5.8%
+7.48M
+159.36%
Sep 12, 2025
State Street Investment Management (US)
8.51M
4.05%
+691.99K
+8.86%
Jun 30, 2025
Kynam Capital Management LP
8.46M
4.03%
-464.78K
-5.21%
Jun 30, 2025
Two Sigma Investments, LP
8.52M
4.06%
+3.25M
+61.72%
Jun 30, 2025
UBS Financial Services, Inc.
5.61M
2.67%
+3.21M
+133.63%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
4.28M
2.04%
+4.08M
+2103.71%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.05M
2.41%
+93.97K
+1.89%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.49%
Invesco Biotechnology & Genome ETF
2.26%
Virtus LifeSci Biotech Products ETF
1.13%
State Street SPDR S&P Biotech ETF
0.66%
ALPS Medical Breakthroughs ETF
0.64%
Invesco NASDAQ Future Gen 200 ETF
0.47%
Direxion Daily S&P Biotech Bull 3X Shares
0.41%
First Trust Small Cap Growth AlphaDEX Fund
0.26%
Principal U.S. Small-Cap ETF
0.23%
Inspire Small/Mid Cap ESG ETF
0.2%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.49%
Invesco Biotechnology & Genome ETF
Proportion2.26%
Virtus LifeSci Biotech Products ETF
Proportion1.13%
State Street SPDR S&P Biotech ETF
Proportion0.66%
ALPS Medical Breakthroughs ETF
Proportion0.64%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.47%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.41%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.26%
Principal U.S. Small-Cap ETF
Proportion0.23%
Inspire Small/Mid Cap ESG ETF
Proportion0.2%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of BioCryst Pharmaceuticals Inc?
The top five shareholders of BioCryst Pharmaceuticals Inc are:
The Vanguard Group, Inc. holds 20.50M shares, accounting for 9.77% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 17.04M shares, accounting for 8.12% of the total shares.
Deerfield Management Company, L.P. holds 12.17M shares, accounting for 5.80% of the total shares.
State Street Investment Management (US) holds 8.51M shares, accounting for 4.05% of the total shares.
Kynam Capital Management LP holds 8.46M shares, accounting for 4.03% of the total shares.
The Vanguard Group, Inc. holds 20.50M shares, accounting for 9.77% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 17.04M shares, accounting for 8.12% of the total shares.
Deerfield Management Company, L.P. holds 12.17M shares, accounting for 5.80% of the total shares.
State Street Investment Management (US) holds 8.51M shares, accounting for 4.05% of the total shares.
Kynam Capital Management LP holds 8.46M shares, accounting for 4.03% of the total shares.
What are the top three shareholder types of BioCryst Pharmaceuticals Inc?
The top three shareholder types of BioCryst Pharmaceuticals Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
RA Capital Management, LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
RA Capital Management, LP
How many institutions hold shares of BioCryst Pharmaceuticals Inc (BCRX)?
As of 2025Q4, 564 institutions hold shares of BioCryst Pharmaceuticals Inc, with a combined market value of approximately 213.88M, accounting for 103.62% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.24%.
What is the biggest source of revenue for BioCryst Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for BioCryst Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
